<SEC-DOCUMENT>0000886163-24-000053.txt : 20240708
<SEC-HEADER>0000886163-24-000053.hdr.sgml : 20240708
<ACCEPTANCE-DATETIME>20240708073830
ACCESSION NUMBER:		0000886163-24-000053
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20240708
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240708
DATE AS OF CHANGE:		20240708

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LIGAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0000886163
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				770160744
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33093
		FILM NUMBER:		241103371

	BUSINESS ADDRESS:	
		STREET 1:		3911 SORRENTO VALLEY BLVD
		STREET 2:		SUITE 110
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		858-550-7500

	MAIL ADDRESS:	
		STREET 1:		3911 SORRENTO VALLEY BLVD
		STREET 2:		SUITE 110
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>lgnd-20240708.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:baee4a51-9d5d-4f75-a915-41ce3fab51c0,g:3040ae82-5ade-491b-8400-5621b617889c,d:65247949399940e2820568aedc305ad6-->
<html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>lgnd-20240708</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-21">0000886163</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-22">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="lgnd-20240708.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-08</xbrli:startDate><xbrli:endDate>2024-07-08</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i65247949399940e2820568aedc305ad6_1"></div><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:173%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:173%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:173%">WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:173%">______________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:173%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:173%">______________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:173%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:173%">Pursuant to Section 13 or 15(d) of the</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:173%">Securities Exchange Act of 1934</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:173%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">July 8, 2024</ix:nonNumeric> </span></div><div style="margin-bottom:7pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:173%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">LIGAND PHARMACEUTICALS INC</ix:nonNumeric>ORPORATED</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:173%">     </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Exact Name of Registrant as Specified in Its Charter)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.538%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 2.12pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 2.12pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-33093</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 2.12pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">77-0160744</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 2.12pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(State or other jurisdiction of</span></td><td colspan="3" style="padding:2px 2.12pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 2.12pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(I.R.S. Employer</span></td></tr><tr><td colspan="3" style="padding:2px 2.12pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 2.12pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Identification No.)</span></td></tr></table></div><div style="margin-bottom:7pt;margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.617%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.203%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:47.780%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 2.12pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">555 Heritage Drive, Suite 200</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 2.12pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">Jupiter</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 2.12pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-9">Florida</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 2.12pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">33458</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 2.12pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 2.12pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">858</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">550-7500</ix:nonNumeric> </span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:173%">(Registrant&#8217;s Telephone Number, Including Area Code)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:173%">N/A</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:173%">(Former Name or Former Address, if Changed Since Last Report)</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:173%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div><span><br/></span></div><div style="padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:144%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-13">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">&#160;&#160;&#160;&#160;Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></div><div style="padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:144%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">&#160;&#160;&#160;&#160;Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div style="padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:144%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule&#160;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div style="padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:144%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule&#160;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Ac</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">t:</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.878%"><tr><td style="width:1.0%"/><td style="width:37.797%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.293%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.610%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">LGND</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">The Nasdaq Global Market</ix:nonNumeric></span></td></tr></table></div><div style="padding-left:24.75pt;text-indent:-22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933(&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company  </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-20">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9744;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i65247949399940e2820568aedc305ad6_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-indent:27pt"><span><br/></span></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 1.01   Entry into a Material Definitive Agreement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 8, 2024, Ligand Pharmaceuticals Incorporated (&#8220;Ligand&#8221;) entered into a definitive agreement (the &#8220;Agreement&#8221;) to acquire APEIRON Biologics AG (&#8220;APEIRON&#8221;) including the royalty rights to QARZIBA&#174; (dinutuximab beta) for the treatment of high-risk neuroblastoma, for $100 million.  Ligand will also pay APEIRON shareholders additional consideration based on future commercial and regulatory events, including up to $28 million if QARZIBA royalties exceed certain predetermined thresholds by either 2030 or 2034, respectively. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APEIRON is a private biopharmaceutical company based in Vienna, Austria that co-developed QARZIBA for the treatment of high-risk neuroblastoma in patients aged 12 months and above. QARZIBA was approved by the European Medicines Agency in 2017 and is commercially available today in more than 35 countries. The patent (method of use) for QARZIBA does not expire until 2034 and as such will have intellectual property protection until 2034. APEIRON receives a royalty on net sales of QARZIBA outside of mainland China from Recordati S.p.A.  and on net sales of QARZIBA within mainland China from BeiGene, Ltd.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Agreement, Ligand will acquire all the outstanding shares of APEIRON for $100 million in cash at closing. Ligand will also pay APEIRON shareholders up to $28 million if QARZIBA royalties exceed certain predetermined thresholds by either 2030 or 2034, respectively, for a total transaction value of up to $128 million and pay additional earn-outs on specific future events. The transaction is subject to a 30-day shareholder objection period and other customary closing conditions and is expected to close in July 2024. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrently, Ligand has also entered into a stock purchase agreement whereby it has committed to investing up to $4 million in invIOs Holding AG, a privately held spin-off of APEIRON. The proceeds will help finance the research and development of three innovative early-stage immuno-oncology assets. APEIRON is entitled to royalties and milestone payments on these assets which will further expand Ligand&#8217;s development stage portfolio. This transaction is expected to close in July 2024.  </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The above summary of the Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Agreement which will be filed as an exhibit to Ligand&#8217;s Quarterly Report on Form 10-Q to be filed with respect to the quarter ended June 30, 2024.</span></div><div><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Item 7.01            Regulation FD Disclosure</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The APEIRON acquisition will be immediately accretive to Ligand&#8217;s earnings per share (&#8220;EPS&#8221;) by approximately $1.00 on an annualized basis. Ligand is increasing its 2024 revenue guidance to be in the range of $140 million to $157 million (previously $130 million to $142 million) and is raising core adjusted EPS guidance to $5.00 to $5.50 (previously $4.25 to $4.75). Royalties are now expected to range from $100 million to $105 million (previously $90 million to $95 million). Guidance for sales of Captisol&#174; is unchanged at $25 million to $27 million and contract revenue is now expected to range from $15 million to $25 million (previously $15 million to $20 million).</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 8, 2024, Ligand issued a press release announcing the APEIRON acquisition. A copy of the press release is furnished herewith as Exhibit 99.1 to this report.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with General Instruction B.2. of Form 8-K, the information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 9.01   Financial Statements and Exhibits.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(d)         Exhibits.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:66.987%"><tr><td style="width:1.0%"/><td style="width:24.498%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:73.302%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Exhibit No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:none" href="exhibit991_apeironligandde.htm">99.1</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Press release dated July 8, 2024</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Adjusted Financial Measures</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ligand reports adjusted earnings per share in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. Ligand&#8217;s financial measures under GAAP include share-based earnings expense, amortization of debt-related costs, amortization related to acquisitions and intangible assets, changes in contingent liabilities, mark-to-market adjustments for amounts relating to its equity investments in public companies, excess tax benefit from share-based earnings, income tax effect of adjusted reconciling items and others. However, Ligand does not provide reconciliations of such forward-looking adjusted measures to GAAP due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation, including adjustments that could be made for changes in contingent liabilities, changes in the market value of its investments in public companies, share-based compensation expense and the effects of any discrete income tax items. Management has excluded the effects of these items in its adjusted measures to assist investors in analyzing and assessing the Ligand&#8217;s past and future core operating performance. Additionally, adjusted earnings per diluted share is a key component of the financial metrics utilized by Ligand&#8217;s board of directors to measure, in part, management&#8217;s performance and determine significant elements of management&#8217;s compensation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Forward-Looking Statements</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This report contains forward-looking statements by Ligand that involve risks and uncertainties and reflect Ligand&#8217;s judgment as of the date of this report. Words such as &#8220;plans,&#8221; &#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;will,&#8221; and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements regarding: the timing of the anticipated transactions and when and whether the anticipated transactions ultimately will close; the potential contributions the acquisition is expected to bring to Ligand, including technologies, collaborations and revenue streams, the potential to secure additional licenses, and development operations; and the expected impact on Ligand&#8217;s future financial and operating results. Actual events or results may differ from Ligand&#8217;s expectations due to risks and uncertainties inherent in Ligand&#8217;s business, including, without limitation: the risk that the conditions to the closing of the transaction are not satisfied; litigation relating to the transaction; uncertainties as to the timing of the consummation of the transaction and the ability of each of Ligand or APEIRON to consummate the transaction; risks that the proposed transaction disrupts the current and future plans and operations of Ligand or APEIRON; whether the acquisition will be immediately accretive to Ligand&#8217;s earnings per share; whether Ligand&#8217;s adjusted 2024 guidance comes to fruition; the success of Ligand&#8217;s investment in invIOs Holding AG; competitive responses to the proposed transaction; unexpected costs, charges or expenses resulting from the transaction; potential adverse reactions or changes to business relationships resulting from the announcement or completion of the transaction; legislative, regulatory and economic developments; and other risks described in Ligand&#8217;s prior press releases and filings with the SEC. The failure to meet expectations with respect to any of the foregoing matters may reduce Ligand&#8217;s stock price. Additional information concerning these and other risk factors affecting Ligand can be found in Ligand&#8217;s prior filings with the Securities and Exchange Commission available at www.sec.gov. Ligand disclaims any intent or obligation to update these forward-looking statements beyond the date of this report, including the possibility of additional license fees and milestone revenues we may receive. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">SIGNATURES</span></div><div style="margin-bottom:20pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-bottom:20pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.993%"><tr><td style="width:1.0%"/><td style="width:40.970%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:56.830%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIGAND PHARMACEUTICALS INCORPORATED</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: July 8, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;margin-top:2pt;padding-left:38.25pt;padding-right:2.25pt;text-indent:-33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/ Andrew Reardon        </span></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:38.25pt;padding-right:2.25pt;text-indent:-33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:    Andrew Reardon</span></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:38.25pt;padding-right:2.25pt;text-indent:-33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:   Chief Legal Officer and Secretary </span></div></td></tr></table></div><div style="margin-top:9pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:36pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit991_apeironligandde.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i904930f20bb044c89f0ec326c5c5fc4e_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><img alt="image_0a.jpg" src="image_0a.jpg" style="height:55px;margin-bottom:5pt;vertical-align:text-bottom;width:158px"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">FOR IMMEDIATE RELEASE</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Ligand to Acquire APEIRON Biologics AG for $100 Million </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"> Acquisition provides Ligand with the royalty rights to QARZIBA&#174;, a highly differentiated, commercial oncology drug marketed in 35 countries by global pharmaceutical company Recordati S.p.A. </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">QARZIBA is the sixth key asset added to Ligand&#8217;s commercial stage portfolio since the beginning of 2023</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Transaction will be immediately accretive to Ligand EPS by an estimated $1.00 per share on an annualized basis with a $0.50 impact to 2024</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Ligand increases 2024 adjusted EPS guidance range by 17% to $5.00-$5.50</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"> </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">JUPITER, Fla., July 8, 2024 - Ligand Pharmaceuticals Incorporated (Nasdaq&#58; LGND) today announced that it has entered into a definitive agreement to acquire APEIRON Biologics AG, which holds royalty rights to QARZIBA</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (dinutuximab beta) for the treatment of high-risk neuroblastoma, for $100 million in cash. In addition, Ligand will pay APEIRON shareholders additional consideration based on future commercial and regulatory events, including up to $28 million if QARZIBA royalties exceed certain predetermined thresholds by either 2030 or 2034, respectively. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">APEIRON is a private biopharmaceutical company based in Vienna, Austria. The company co-developed QARZIBA for the treatment of high-risk neuroblastoma in patients aged 12 months and above. QARZIBA was approved by the European Medicines Agency in 2017 and is commercially available today in more than 35 countries. APEIRON receives an undisclosed royalty on net sales of QARZIBA outside of mainland China from Recordati S.p.A, a leading global pharmaceutical company with a presence in over 150 countries and sales of more than $2.2 billion,</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and on net sales of QARZIBA within mainland China from BeiGene, Ltd. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;The addition of QARZIBA</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">to our commercial royalty portfolio further supports our growth strategy to invest in high-value medicines that deliver significant clinical value and generate predictable and long-term revenue streams for our investors,&#8221; said Todd Davis, CEO of Ligand. &#8220;QARZIBA is the only immunotherapy for high-risk neuroblastoma marketed across Europe and in other parts of the world. We believe this drug will be a meaningful contributor to our royalty revenue which is now driven by a diversified portfolio of 12 key commercial-stage products.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Peter Llewellyn-Davies, CEO of APEIRON commented, &#8220;This transaction is an important milestone for our company and shareholders. We have spent more than 20 years</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> translating academic research into therapeutic products for diseases with high unmet needs. Our team was honored to </font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Based on midpoint of revised and prior EPS range.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Based on 2023 reported financials. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">help bring </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">QARZIBA to the young patients who need it. We appreciate that Ligand recognizes the long-term potential of this critical drug for a rare pediatric cancer.&#8221;</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Transaction Terms </font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Under the terms of the agreement, which has been unanimously approved by both the</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Board of Directors at Ligand and APEIRON&#8217;s Supervisory Board, Ligand will acquire </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">all the outstanding shares of</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">APEIRON for $100 million in cash at closing. Ligand will also pay APEIRON shareholders additional consideration based on future commercial and regulatory events, including up to $28 million if QARZIBA royalties exceed certain predetermined thresholds by either 2030 or 2034, respectively. The transaction is subject to a 30-day shareholder objection period and other customary closing conditions and is expected to close in July 2024. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Concurrently, Ligand is also entering into a stock purchase agreement whereby it has committed to investing up to $4 million in invIOs Holding AG, a privately held spin-off of APEIRON. The proceeds will help finance the research and development of three innovative early-stage immuno-oncology assets. APEIRON is entitled to royalties and milestone payments on these assets which will further expand Ligand&#8217;s development stage portfolio. This transaction is expected to close in July 2024.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Financial Guidance Update</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The APEIRON acquisition will be immediately accretive to Ligand&#8217;s earnings per share (EPS) by approximately $1.00 on an annualized basis. Ligand is increasing its 2024 revenue guidance to be in the range of $140 million to $157 million (previously $130 million to $142 million) and is raising core adjusted EPS guidance to $5.00 to $5.50 (previously $4.25 to $4.75). Royalties are now expected to range from $100 million to $105 million (previously $90 million to $95 million). Guidance for sales of Captisol&#174; is unchanged at $25 million to $27 million and contract revenue is now expected to range from $15 million to $25 million (previously $15 million to $20 million). </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">McDermott Will &#38; Emery and E+H Rechtsanw&#228;lte GmbH </font><font style="background-color:#fefefe;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">served as Ligand&#8217;s legal counsel. Baker McKenzie and DORDA served as APEIRON&#8217;s legal counsel.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About QARZIBA</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:700;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">QARZIBA is a monoclonal antibody that is specifically directed against the carbohydrate moiety of disialoganglioside 2 (GD2), which is overexpressed on neuroblastoma cells. Dinutuximab beta was approved by the European Medicines Agency in 2017 for the treatment of high-risk neuroblastoma in patients aged 12 months and above, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and stem cell transplantation, as well as patients with history of relapsed or refractory neuroblastoma, with or without residual disease. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dinutuximab beta was originally discovered by EMD Lexigen Research Center and ultimately developed by the Children&#8217;s Cancer Research Center (CCRI) and European Neuroblastoma Research Network (SIOPEN) for the treatment of high-risk neuroblastoma. APEIRON in-licensed dinutuximab beta from CCRI and SIOPEN in 2011, and upon completing the clinical development, out-licensed the exclusive global commercialization rights to EUSA Pharma (UK) Limited in 2016. QARZIBA is marketed outside of mainland China by the global pharmaceutical company Recordati S.p.A., which acquired EUSA Pharma (UK) Limited in 2022.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About APEIRON Biologics AG </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">APEIRON Biologics is a private biopharmaceutical company based in Vienna, Austria. The company co-developed QARZIBA&#174; (dinutuximab beta), a high-risk neuroblastoma drug, which it licensed to EUSA Pharma (UK) Limited (now a Recordati S.p.A. company) in 2016. APEIRON is entitled to an undisclosed royalty on global net sales of QARZIBA. The company also maintains a portfolio of more than 400 patents including the intellectual property and licenses for an early-stage immuno-oncology portfolio currently being developed by invIOs Holding AG which was spun-off from APEIRON in 2022. For more information visit </font><font style="color:#245be2;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">www.apeiron-biologics.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About Ligand Pharmaceuticals </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Ligand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this by providing financing, licensing our technologies or both. Its business model seeks to generate value for stockholders by creating a diversified portfolio of biopharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Ligand&#8217;s goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable and diversified manner. Its business model focuses on funding programs in mid- to late-stage drug development in return for economic rights, purchasing royalty rights in development stage or commercial biopharmaceutical products and licensing its technology to help partners discover and develop medicines. Ligand partners with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) in order to generate its revenue. Ligand&#8217;s Captisol&#174; platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Ligand has established multiple alliances, licenses and other business relationships with the world&#8217;s leading biopharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International. For more information, please visit </font><font style="color:#245be2;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">www.ligand.com.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Follow Ligand on X &#64;Ligand_LGND.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We use our investor relations website and X as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Investors should monitor our website and our X account, in addition to following our press releases, SEC filings, public conference calls and webcasts.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Adjusted Financial Measures</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Ligand reports adjusted earnings per share in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. Ligand&#8217;s financial measures under GAAP include share-based earnings expense, amortization of debt-related costs, amortization related to acquisitions and intangible assets, changes in contingent liabilities, mark-to-market adjustments for amounts relating to its equity investments in public companies, excess tax benefit from share-based earnings, income tax effect of adjusted reconciling items and others. However, Ligand does not provide reconciliations of such forward-looking adjusted measures to GAAP due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation, including adjustments that could be made for changes in contingent liabilities, changes in the market value of its investments in public companies, share-based compensation expense and the effects of any discrete income tax items. Management has excluded the effects of these items in its adjusted measures to assist investors in analyzing and assessing Ligand&#8217;s past and future core operating performance. Additionally, adjusted earnings per diluted share is a key component of the financial metrics utilized by Ligand&#8217;s board of directors to measure, in part, management&#8217;s performance and determine significant elements of management&#8217;s compensation.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Forward-Looking Statements </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This news release contains forward-looking statements by Ligand that involve risks and uncertainties and reflect Ligand's judgment as of the date of this release. Words such as &#8220;plans,&#8221; &#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;anticipates,&#8221; and &#8220;will,&#8221; and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements regarding&#58; the timing of the anticipated acquisition and when and whether the anticipated acquisition ultimately will close&#59; the potential contributions the acquisition is expected to bring to Ligand, including technologies, collaborations and revenue streams, the potential to secure additional licenses, and development operations&#59; and the expected impact on Ligand&#8217;s future financial and operating results. Actual events or results may differ from Ligand&#8217;s expectations due to risks and uncertainties inherent in Ligand&#8217;s business, including, without limitation&#58; the risk that the conditions to the closing of the transaction are not satisfied&#59; litigation relating to the transaction&#59; uncertainties as to the timing of the consummation of the transaction and the ability of each of Ligand or APEIRON to consummate the transaction&#59; risks that the proposed transaction disrupts the current and future plans and operations of Ligand or APEIRON&#59; whether the acquisition will be immediately accretive to Ligand&#8217;s earnings per share&#59; whether Ligand&#8217;s adjusted 2024 guidance comes to fruition&#59; the success of Ligand&#8217;s investment in invIOs Holding AG&#59; competitive responses to the proposed transaction&#59; unexpected costs, charges or expenses resulting from the transaction&#59; potential adverse reactions or changes to business relationships resulting from the announcement or completion of the transaction&#59; legislative, regulatory and economic developments&#59; and other risks described in Ligand&#8217;s prior press releases and filings with the SEC. The failure to meet expectations with respect to any of the foregoing matters may reduce Ligand's stock price. Ligand disclaims any intent or obligation to update these forward-looking statements after the date hereof. Additional information concerning these and other risk factors affecting Ligand can be found in prior press releases available at </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">www.ligand.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> as well as in Ligand's public periodic filings with the Securities and Exchange Commission available at </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">www.sec.gov</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Ligand disclaims any intent or obligation to update these forward-looking statements beyond the date of this release, including the possibility of additional license fees and milestone revenues we may receive. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Contacts</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">For Ligand&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Investors</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Michael Jeong</font></div><div style="text-align:justify"><font style="color:#245be2;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">investors&#64;ligand.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(561) 214-4232</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">LifeSci Advisors</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Bob Yedid</font></div><div style="text-align:justify"><font style="color:#245be2;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">bob&#64;lifesciadvisors.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(516) 428-8577</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Media&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Kellie Walsh</font></div><div style="text-align:justify"><font style="color:#245be2;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">media&#64;ligand.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(914) 315-6072</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>lgnd-20240708.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:baee4a51-9d5d-4f75-a915-41ce3fab51c0,g:3040ae82-5ade-491b-8400-5621b617889c-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:lgnd="http://www.ligand.com/20240708" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.ligand.com/20240708">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lgnd-20240708_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lgnd-20240708_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.ligand.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>lgnd-20240708_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:baee4a51-9d5d-4f75-a915-41ce3fab51c0,g:3040ae82-5ade-491b-8400-5621b617889c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_SecurityExchangeName_68184075-62e7-414f-81e8-fd1a27d07c73_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_cc965a40-3426-4581-ac04-d67f5f89e5f7_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_f4813d97-125c-4938-bba2-4d15d6a13fab_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_4ef76811-2331-422f-88f1-1303b26d3aaa_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_dcaecefe-ceae-42f2-a3df-da2a951f7417_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_aac10e7f-cff5-44e4-b1e3-e47badf413f3_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_7a31e7c9-05a4-4bdb-8d3f-8650eccad2dd_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_03eec658-ee99-4439-a285-12feb0b5a6f0_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_fcf1660b-6af3-4a1d-873a-37334ba4f514_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_17386ffa-8ee9-45fd-8ad7-b2335233a1ab_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover page.</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_10ebe547-f182-44eb-9452-eab4cbca27c4_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_d82ccc03-776f-42fe-8c0f-719e739d3dbe_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_abf470ec-0ddb-442a-8e73-b8563d0584e4_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_906fe884-5b49-40d2-b6f3-e4ecf2dc2536_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_3e3731b2-f2cf-4b95-8f68-41233f05f0de_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_b2750ab8-d2e6-4170-97b1-6664b4655363_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_88d1606b-b123-46f9-b9b4-c2bec47cd0db_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_580f5818-d9e4-4253-aecc-7f6e9d5b078a_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_00085907-7af0-4091-98e3-671b55a91b20_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_b0077efc-f26f-45e3-bd55-b9b8cb466e5c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_3adcdae2-38ac-46eb-8276-eb5e0fe4aeee_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_a790c9a2-7211-4ca9-b7bb-d70b131a9c4a_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_8954ebd6-c141-409b-876e-5b3248db3563_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_ee2cfbdc-383d-432b-bc0b-651dc34e5546_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>lgnd-20240708_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:baee4a51-9d5d-4f75-a915-41ce3fab51c0,g:3040ae82-5ade-491b-8400-5621b617889c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.ligand.com/role/CoverPage" xlink:type="simple" xlink:href="lgnd-20240708.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_07bda0d6-b4a8-49b2-be55-9d57d8a4e0a8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_53f3d6b0-2fc5-414d-9306-969acfa7cf05" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_07bda0d6-b4a8-49b2-be55-9d57d8a4e0a8" xlink:to="loc_dei_EntityCentralIndexKey_53f3d6b0-2fc5-414d-9306-969acfa7cf05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_f7868f4f-ec25-47bb-ab29-7752c7dd233b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_07bda0d6-b4a8-49b2-be55-9d57d8a4e0a8" xlink:to="loc_dei_AmendmentFlag_f7868f4f-ec25-47bb-ab29-7752c7dd233b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_327b3e29-ed08-496d-8be3-469b667f9838" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_07bda0d6-b4a8-49b2-be55-9d57d8a4e0a8" xlink:to="loc_dei_CurrentFiscalYearEndDate_327b3e29-ed08-496d-8be3-469b667f9838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_112cf5e3-bd29-4ce8-a2f3-18d72705fe2e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_07bda0d6-b4a8-49b2-be55-9d57d8a4e0a8" xlink:to="loc_dei_DocumentType_112cf5e3-bd29-4ce8-a2f3-18d72705fe2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_dbd4b7a9-c4e1-4d03-8074-fe80700b34ca" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_07bda0d6-b4a8-49b2-be55-9d57d8a4e0a8" xlink:to="loc_dei_DocumentPeriodEndDate_dbd4b7a9-c4e1-4d03-8074-fe80700b34ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_b2626ae0-216a-440e-9de7-29f37aa117e3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_07bda0d6-b4a8-49b2-be55-9d57d8a4e0a8" xlink:to="loc_dei_EntityRegistrantName_b2626ae0-216a-440e-9de7-29f37aa117e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_af62af83-4adf-4c2d-b547-eacd19ba04ac" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_07bda0d6-b4a8-49b2-be55-9d57d8a4e0a8" xlink:to="loc_dei_EntityIncorporationStateCountryCode_af62af83-4adf-4c2d-b547-eacd19ba04ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_5b6b2a39-e106-42c2-9ad2-8ddde4339a46" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_07bda0d6-b4a8-49b2-be55-9d57d8a4e0a8" xlink:to="loc_dei_EntityFileNumber_5b6b2a39-e106-42c2-9ad2-8ddde4339a46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_56a6c765-f2aa-4de6-8c57-18949ebae5e1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_07bda0d6-b4a8-49b2-be55-9d57d8a4e0a8" xlink:to="loc_dei_EntityTaxIdentificationNumber_56a6c765-f2aa-4de6-8c57-18949ebae5e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_ad0cca7d-f8bf-4b31-8e32-56c93a84b880" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_07bda0d6-b4a8-49b2-be55-9d57d8a4e0a8" xlink:to="loc_dei_EntityAddressAddressLine1_ad0cca7d-f8bf-4b31-8e32-56c93a84b880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_cc11c07b-5481-4562-ba0a-972400d278e1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_07bda0d6-b4a8-49b2-be55-9d57d8a4e0a8" xlink:to="loc_dei_EntityAddressCityOrTown_cc11c07b-5481-4562-ba0a-972400d278e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_d0aa6008-d6cb-4bcb-ab13-558de618e321" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_07bda0d6-b4a8-49b2-be55-9d57d8a4e0a8" xlink:to="loc_dei_EntityAddressStateOrProvince_d0aa6008-d6cb-4bcb-ab13-558de618e321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_0e0a972d-a6d6-4a18-a2f3-de4168423701" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_07bda0d6-b4a8-49b2-be55-9d57d8a4e0a8" xlink:to="loc_dei_EntityAddressPostalZipCode_0e0a972d-a6d6-4a18-a2f3-de4168423701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_8af205ed-0d49-4e1b-b62a-4a8cef15457c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_07bda0d6-b4a8-49b2-be55-9d57d8a4e0a8" xlink:to="loc_dei_CityAreaCode_8af205ed-0d49-4e1b-b62a-4a8cef15457c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_7880fe74-b7fb-47ee-a9b5-18bf15cba6e4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_07bda0d6-b4a8-49b2-be55-9d57d8a4e0a8" xlink:to="loc_dei_LocalPhoneNumber_7880fe74-b7fb-47ee-a9b5-18bf15cba6e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_fb22f9a1-7ff7-4159-87be-488369d3d663" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_07bda0d6-b4a8-49b2-be55-9d57d8a4e0a8" xlink:to="loc_dei_WrittenCommunications_fb22f9a1-7ff7-4159-87be-488369d3d663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_49e516ea-79fa-4b34-adcd-ce0cc829acf7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_07bda0d6-b4a8-49b2-be55-9d57d8a4e0a8" xlink:to="loc_dei_SolicitingMaterial_49e516ea-79fa-4b34-adcd-ce0cc829acf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_39959ecf-cb43-4bb3-aacf-e5a6490e800f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_07bda0d6-b4a8-49b2-be55-9d57d8a4e0a8" xlink:to="loc_dei_PreCommencementTenderOffer_39959ecf-cb43-4bb3-aacf-e5a6490e800f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_d4f0bb47-cba0-48d9-a685-2e8ccec950d6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_07bda0d6-b4a8-49b2-be55-9d57d8a4e0a8" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_d4f0bb47-cba0-48d9-a685-2e8ccec950d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_e6008373-b6aa-469b-86cc-2355b68474fc" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_07bda0d6-b4a8-49b2-be55-9d57d8a4e0a8" xlink:to="loc_dei_Security12bTitle_e6008373-b6aa-469b-86cc-2355b68474fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_0456b9c6-c43e-4ba6-adcf-60b3b46bddc1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_07bda0d6-b4a8-49b2-be55-9d57d8a4e0a8" xlink:to="loc_dei_TradingSymbol_0456b9c6-c43e-4ba6-adcf-60b3b46bddc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_5f7aaa11-bebd-45c6-8442-180e4657e4aa" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_07bda0d6-b4a8-49b2-be55-9d57d8a4e0a8" xlink:to="loc_dei_SecurityExchangeName_5f7aaa11-bebd-45c6-8442-180e4657e4aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_333ef1e2-9e9e-4d6e-ac9b-fa6bd04093f8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_07bda0d6-b4a8-49b2-be55-9d57d8a4e0a8" xlink:to="loc_dei_EntityEmergingGrowthCompany_333ef1e2-9e9e-4d6e-ac9b-fa6bd04093f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_0a.jpg
<TEXT>
begin 644 image_0a.jpg
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M25(V[H2FQL\GC[IT5N8RE[G,92YSF<M<YC*7N<QEOG;S.OA8IW&]XO=\]<1
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MF4[J6K@64$%S5$?D1"#X,^Q'J,JXINJ_4I5(H\W8C'X.(:K/D:1$;Z<"+W9
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MO&/@@%-+!0:F6B\8#$3&NB-#[>=?O#M[]?_\X+[Y"@?]B,:X^,I6!6)216$
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MO8']57T9U"8L\N",DK#(#W9**Q>*UN,+U@?^X^N]SY_H"H_"U;>$$JWA&=?
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M%&@#-0%EGT D)6?M>$FI?'6)'C_/ID"G#:G9U;936P$J"MKCLI5_$"Y OO2
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MXNS?TD0Q.=<-!>;D'*K6M^XYUA/>X^H?])FPDREZ2F=-Q=D1ML)VO$N2$J@
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ML9DN?%4A$1]NF:2$L;FCN;80&22]=TN;;._=_?$O_PC>B0,)S"K5:IFT,?+
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M2?F,L>@E!XZP""&711>=-DI*._#"#'H2KNQQR]J3>E,@. Z[HE,5^@S9E9D
M2_9#IG4<RU*BVA=M[ FGV_OV];T@\? \&S3UM3@H+>*@^,2=+]L\7WQ;HE%4
MZP>_6GAZ:%^/D?;T9[WA&5]TEAM^_2CVSIN>-9>4< OJR998R2]?(5F>\(3'
M.D.7WWG/8?P\CY <D4Y5O>N%'0Y/.%2M:OA/U5I<*)<JUF^/6-LOGO$;(_0<
MINT'''JJM3\.A=8Q,.N-Y,[>-H[$K(6D!,C1*9&4,DK9I" C+:B[@=EV+>O5
MXEO-?5_XGWOHT0)<+,22&=@VH"Z&H#O'.?)_M&B%_SS=I8_Z=/2;2E+:U/S;
MIG L9PPB*85U1B1E<V+[>NX=FTQ2\G%72DJ$8NUF#G& *Y3H"8\]*[+G<7Z"
M*Z>8.D5^K&N#4R)G!9,K%<L%;(9(8NXU-W0&!^D^S"5)R3=2*DF)!'!L43=(
M571J6=B4H*[)QA#3F^DM?</MVG"7N?\#G_P6=7ED17S[)-^=RQ,\'-9 *E#8
MA6U@5#]\:*$[N"^@I>VS^ 9)2HI*:8P+]L.M1FG($V*G1+4O IVO/Y+J,?9_
MY*:[<0C8-$]V&BA1_)GMFT8I8?8+I2J<ZM[4-8'@L#>8Z(C,;NE51Z_;L-JY
MG>LF9NTE95N8W +[ 5J/>J2S V8\$)UXUL#P0X=H/\5BL52A&[47E6V01*/U
M;!]\:!RVD%='/[9HW?'C([U_DG3KXW_\W"'(2#^-&J4@)M75SAQNK3C%L$JX
MNI^JI$1&8'@B*7G_*X_87" CK3#CZ$P;G>U*!HR1[%_]$RJ7ZAG_%:J,:FOH
M?3GTD4Z7J'YS>.;-7=I^2$J4AK(H!1?19G$L9PPJ>A=)*:P;(BF;$]O7<^]X
M DFY,5\B@J36):5'R_FT*?4T?'P%2]L22F'NUN,=H<$K)O\&AF2_:($2#6.K
MV1MG@>R-K@PLE2IE>+#'JY;Y%[F -K8D*1OTI')00!FV2@DGQEXO;%;4XWD<
MH4G_]E1G=.0YSQ_Y[:*UJ)2!+1B426'"6GI!)994V'W$LF;?^"X856=XALWF
M%$C*ME#&T3O>$YF(79([5*+^%,>O/W6V8:*P3X%^ES3 M^[MW'9YIT:/,N;H
MG\80E!G7CM+\G Y)2>5F=TPL*5LC-.:,D.N<6/S/]EQUJ$"%CKW!N? ^:;?X
MBV55'[22UM/YB.+"(CSK8M7ZT&?N/"<Z<LZ%F9;>$4<P 3&).72:+SI-SPFK
M9_"IP=5-DE)>(L)9.],E)6@SZ+%V,&PL^_6QX(N2CZEWWG)Y<9$M;R_VAQ)=
MW6]9"_QZI!YMD&X8(0/C3I/;2,UEK3RBL)$122FL,R(IFQ/;W7/OV$R2LC62
M:E624H>>7)*4KB@]G17VY@TGN[3!U[WC8W U=$;53C1UC>R7>**5I2I=$D@#
M2OCSHP>K6_5]74:2]T;9P;'J>A)@C>V@Z$Y+M9+<;CUMPJ8$U>W44MXHPN7Q
MSO"NM[SG$_/*AC"O61?/,%'\S7.Z'^E(V7I@T>H(7@8_QGTGA5D,21'B^%;3
M*"85C=_2QKG.@9>YM&R',=G1>_G7?_ (6;!]=/A/[H/Y R>);!YK2B522NC^
M7S+\BJV188\VYHV0TR9Q6^M\&P[1^+'96&M)N3Q6H95\#3/\0$LHY3-37=K^
M5[[Y@Y E]&BF)?^#/[1_K*&5*AGJ#E@<D2^F.%JU7O..C_K[K^C>D6O74D@
M5.66WHFV4-)CGK)*45Y+)*5(RCJ>2 ;VAGZ3/FH3G<$]__W=1_)4T9CHNAZ4
M": 5^,]P,$"2$B6(@OWO'SS2$T0\3_>*DT79S03E8_>50A,ADE)89T12-B?D
M\;' O6,S7?CZ1)(2W;\[-M=F9-W!\:>;^S_X_[YNVULM2QQ)-/:.I2H]!I8D
MY9&J]='/?[<C.-2!\(B\ISH6Q5YPK"J 8.\$]TK@Z+;/K=F\L%EQ0IGHZ<".
M T\[?R><TJ/\LD>KE*_W=PU&!85 UYHBV#I<**.[_?M_O;DCN-\;3J+CM,<G
M.:9GE0*YJ%I-0\.I?U6G_A6!+7-.;1H6Z-/C7<:^O;FK#U>M(] F9.#PGWPA
M;H. H:0B;,Z7"_Q\T?^X^6YO_Z7._D%':)(24Y>42\<Z':UX#5E[28DUU+M1
MK$S+["78/T1F(?^Z8JES8Z/O^^0W<$2Z1*)^%)[Q44CGTT7X=-E@J5*A*Y=1
M._APK&)=//R*]FV#G=OG6OHF8750_HY@0KV>U,[@4T.9'Q!)R5D329GQFIGV
M4-QIHK%D7? J^NA;WWT3ZI>JFFZ8I/X1T$>*T.!>Z N47K&RH"SA=_EZ/*^&
M\<FKH'6H>'[%X80-CHK>8?,B*87U021E<U(/B8AFDI0F@</!S!HE98MZYP?F
M_6/G18:^_:-';7OC1&.FND9V39C@G2CZAU_"&GBDF=>_IU,;(S='WI,B;!5[
M,11 L)B<8412GD&T:RE(!5]T.A"-YU[_;D2<W#,NT A4V:I"'/!G,BJZ#K98
MJ<RCIT.?^%#>ZGU>@F)3C=Y)TV[,M85G*!XUZ3W@V+/J[Y:U'27MCL=.##8C
M(T2/[C>2@?!0MW;I]^];(/7"AZ])2B2'@F.2+"JQ?%4LDO28984O3?G-$?]
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M.F)Z!8Z6\BY%"$)SH*)WV+Q(2F%]$$G9G-A!"?>.)Y"4JL.H3^JC_>V&E)1
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M>P;%M"IIF-0Y5NXX ^JN:P Q($'=U8]KUD5W=5UUC2CL&C" ZZ(D0=> J("
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M*KVFG:]<@8(S.*ZG<M;-=SRPQ=@'X>&-S&S0IC:$IQQ=4_"P,'+X5G*O-.H
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MD*I4K8RO$J)']FR?K#?HN6B'GJX/T94C!.I^HU\[-W73_SX,VT $;E\K1 '
M MCR59E@A6K8_I;*!8X?^]]Z[\%F8[=3'VLP3K 'W85CC>J^15(*ZX8\^%J;
MV%T:]XXGLZ2$LT)PX REW5K"V=[7K.W^XHUWJ1!S;NXIFNX=P5/Y8NUB@6V2
M71<%(*5"H43W:N"U\">?_MJM+1V[?<%^N+[GMH]NQ(_OV$^'L", LGG;B57
M.7 TP%$IL_STUH"CUX5]>D=L]YI3]9U)__;7-)W]&KJD;<8\H9Y=B;<N24IJ
MF,JYEPT 2Q'E1D$'2\H'FO5]/CV&_)8#'3H!F =0OGTMH?Q65P$^*AD#ST.#
MFABQK<; W??3\(59BII47NP<T:)RA5@S1W6-BO[9 PLMP5TTJ$]DZL@2JRE8
M4MKA[S))6:^EZK6$6Q_=TC5\RR\/PL)1 O3L*U<P9 C#GU11T6N6"^HBPF>^
M<7L@V!^(SM:%IE0@R[^O5#T)^XJVYXJ@NJ@I2;F>([X^6YQ:TA>9A*BKVS88
M,(?/.&?TQ_<^@<8[3XVV4"R0?T..BT6:=)5RS260+Y*G0Y:1W\.+E/[TY_=-
M'W@CZ<ERP6 W?E)#)"4YEF,E*96/JF;%#M7@0&A?]6$*DCE.)O/#GZ@FIMK:
MBI_";L_MB 7.WN\(QENWSWB"PX%0[ZN&WW#3S_X( 7"8IP.97^!F3ME&KNU5
M!2]VX<S/+RX6J$!>T?]:O];;O'V:'W!==H;"289(2F&=$4E9F]BQ$?>.1Y&4
M]N!OY45]M+^M*4G9J"7AKUA2IIHCZ:;0@/'*Y!\.V7-45D9'I/'3$6TH#X98
MK'ROLEC,(_S*L=*  [WT'S_;HN]I"H_X(\FF[;//;1]7UX\)]F 4>;"L\H7H
M?IWJ\E54>CQ":JI0%7FLW%X67174FS8(2:?<D8NA#?Y_9XZ[(E/-.R80/>Q)
MER4E%P*OV@)#E8N2E+ *DI3\+J5/1VM%QJ>7)"6+#>7;UQ*R/78XE"]L424
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M.'L8GK#)G'9L2VUYT>NA*OE45V9*.&D022FL,R(I:Q/5;U$O!4YB20D/@\@
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M!Y@M>FZ"Q]S#1[4[O[_' >L?GK2NN_GWK[OR,R_I>=W6KD%/^RY?Y[ZF\'#
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M*NBY11I]FDZG6*0QTNSR)[BYD<6JDWPF%.E: 7*'7\P7LS@@97(Q3R> =OW
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MI4+_TZ*<&SD-!3<J_*$:GL?'P_,XPR0I(>!/M,*IEI1V+E@2+[U+R;E%0N5
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MXG=O:PE=U&2B<Y]PZ20IU;.CW#6H>Y4K#WHL67J7<FJCL6Q>2CK5%8O*"V7
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M78M9L+)/D;8D18,20^'QP_#4B/ _:1YL^M:/?[?%[$-D25["G'0$D_ZN67X
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M.")3MJ2DF[&J#=J>;46F3GKH"@((308B,Y#<@<Z^E^T]\&21QFJ"V<S/L[I
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M?-2RO%KOINUQKS;>V!EW:1//\1BQK2^9<07[W!V[-H7W_8F?CCUL67/\4B7
M"L 6M1&_ L$I"((@"((@"((@G%) #T(PMG2/N8(#OG#2I67JML6?X]#3_^?,
MH:;ML]YPTF.,!8S10+!_DSG4&NRK8J Y1#2%!@)ZGR (@B (@B (@G J8@Y!
M3[9U3]1O&_%'9@+1_<_9:&0\9Q_XJV#<&9ERZ$F7GO*',^Y@S&^D_'J&F01>
M?0IXC"FW.>D,"X(@"((@"((@"*<6[G#*:\:]YKBC8[AY^W1C,.7H2#ZG+II4
MU$>2#6&BT4R[#,4$:#0FF>DJU!9!$ 1!$ 1!$ 3A5 'RT&TDW4:<2;IU$HR0
ME'$ /5F6E&E%HSG18$ZHM,&<K+#B1P5!$ 1!$ 1!$(13 ;KI:$)2*NS;D,^!
M:&2@(9>!KRMIHYFL4+Z!*0B"( B"( B"()S:&.G_/V4G.U^I$L*W     $E%
&3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140091082066864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th"><div>Jul. 08, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000886163<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jul.  08,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">LIGAND PHARMACEUTICALS INC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33093<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">77-0160744<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">555 Heritage Drive, Suite 200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Jupiter<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">33458<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">550-7500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LGND<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$
MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7<K_WUE[O)I#-ZG7TZSFN4
M?VFK :?MNYO/D_QSZ.2?IY/734+.<+PL"?'[(UMAAR=N.Q-R.AQG0GS/]O:1
MI24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG LR+7E$8D19_(
M+;KD$3BU20TR$S\(G8:8:E < J0),9:AAOBTQJP1X!-]M[X(R-^-B/>K;YH]
M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M
MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZ<TT#PE"\D^DJ1CVFS(Z=T)LWH
M,QK!1J\;=8=HTCQZ_@7YG#4*')$;'0)G&[-&(81IN_ >KR2.FJW"$2M"/F(9
M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+
MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T
M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M_'MH:)'F9\Z5T'""S2^WC,):,"_ \[40^J-ACK'%?R$&_P!02P,$%     @
MSCSH6)^@&_"Q @  X@P   T   !X;"]S='EL97,N>&ULW5=M:]LP$/XK0C]@
M;F)JXI$8MD!AL(U"\V%?E5AV!'KQ9+ES^NNGLVPG:75EW8>QS:')W3VZNT=W
M)YFN6W>2_.'(N2.]DKK=T*-SS?LD:0]'KEC[SC1<>Z0R5C'G55LG;6,Y*UMP
M4C)9WMQDB6)"TV*M.W6G7$L.IM-N0V]H4JPKH\^6E :#7\H4)X],;NB62;&W
M8EC+E)"G8%Z"X6"DL<1Y*GQ#%V!IGP*\"!JP'.,HH8T%8Q(RA._]N/P9,&FM
M5X64,\$E#89BW3#GN-5W7AD6#\87$!GEW:GQ#&O+3HOE+3T[##\^R=[8DMLY
MS8).IF(M>05TK*B/\.M,DP#HG%%>* 6KC68#A\EC%'S8 Y?R 5KXK;J*W5<D
M].)3"6T@L-5)](1&,80)"L2_C!9B7X2]_:VPI!&/QGWL_&[TH'_OC./WEE>B
M'_2^FO-CT1=X=-8T\O1!BEHK'O;^RPF+-9O\R-%8\>2SP:0<O(%;2AZY=>)P
M:?EA6;/CO9NFJ:]PSLM_D/.?K7/--;=,7I+VH_\W5_DMC)/Q]%P<T:L#.EL)
M7(0;^A7N5WGF0/:=D$[H43N*LN3ZQ3GUX1W;^PO\*KY?7_**==+M9G!#S_(7
M7HI.Y?.J>ZC+N.HL?X;[:)'-M[#/)73)>UYN1]76^T$D7O!9QP<<GB-WPQ-'
M,)^ Q1' L#P8 \PG>&%Y_J?]K-#]! SCMHHB*]1GA?H$KQBR'3Y8GKA/[I_X
M3O,\3;,,J^AV&V6PQ>J69? 7CX9Q P\L#V1Z6ZWQ;N,3\OH<8#U];4*PG>*3
MB.T4KS4@\;J!1Y['NXWE 0^L"]CL0/YX'IBIN$^:0E<Q;M@)QI$\QQ"8Q?B,
M9AE2G0P^\?Y@IR1-\SR. !9GD*88 J<11S &P %#TG1X#SY['R73>RHY_U=3
M_ 102P,$%     @ SCSH6)>*NQS     $P(   L   !?<F5L<R\N<F5L<YV2
MN6[#, Q ?\70GC 'T"&(,V7Q%@3Y 5:B#]@2!8I%G;^OVJ5QD L9>3T\$MP>
M:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA]) 1-MC0[!:+#Y +AEF
MM[UD%J=SI%>(7->=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2?S+W\PPU1>5*(Y5;
M&GC3Y?YVX$G1H2)8%II%R=.B':5_'<?VD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ
M8K3^-8+)#^Q^ %!+ P04    " #./.A8&445]3<!   G @  #P   'AL+W=O
M<FMB;V]K+GAM;(U1T6[", S\E2H?L!:T(0U17D#;D*8-C8GWT+K4(HDKQX6-
MKY_;JAK27O:4W-FZW%T6%^+3@>B4?'D78FYJD6:>IK&HP=MX1PT$G53$WHI"
M/J:Q8;!EK '$NW2:9;/46PQFN1BUMIS> A(H!"DHV1%[A$O\G7<P.6/$ SJ4
M[]ST=P<F\1C0XQ7*W&0FB35=7HCQ2D&LVQ5,SN5F,@SVP(+%'WK7F?RTA]@S
M8@\?5HWD9I:I8(4<I=_H]:UZ/(,N#Z@5>D(GP&LK\,S4-AB.G8RF2&]B]#V,
MYU#BG/]3(U45%K"FHO409.B1P74&0ZRQB28)UD-N5G0&3K;V"%TH?653#@%%
MG=W4Q7/4 6_*P>-HK(0* Y1OJA65UY**+2?=T>M,[Q\FCUI&Z]Q*N??P2K8<
M<XY_M/P!4$L#!!0    ( ,X\Z%@D'INBK0   /@!   :    >&PO7W)E;',O
M=V]R:V)O;VLN>&UL+G)E;'.UD3T.@S ,A:\2Y0 U4*E#!4Q=6"LN$ 7S(Q(2
MQ:X*MR^% 9 Z=&&RGBU_[\E.GV@4=VZ@MO,D1FL&RF3+[.\ I%NTBB[.XS!/
M:A>LXEF&!KS2O6H0DBBZ0=@S9)[NF:*<//Y#='7=:7PX_;(X\ \PO%WHJ45D
M*4H5&N1,PFBV-L%2XLM,EJ*H,AF**I9P6B#BR2!M:59]L$].M.=Y%S?W1:[-
MXPFNWPQP>'3^ 5!+ P04    " #./.A899!YDAD!  #/ P  $P   %M#;VYT
M96YT7U1Y<&5S72YX;6RMDTU.PS 0A:\295LE+BQ8H*8;8 M=< %C3QJK_I-G
M6M+;,T[:2J 2%85-K'C>O,^>EZS>CQ&PZ)WUV)0=47P4 E4'3F(=(GBNM"$Y
M2?R:MB)*M9-;$/?+Y8-0P1-XJBA[E.O5,[1R;ZEXZ7D;3?!-F<!B63R-PLQJ
M2AFC-4H2U\7!ZQ^4ZD2HN7/08&<B+EA0BJN$7/D=<.I[.T!*1D.QD8E>I6.5
MZ*U .EK >MKBRAE#VQH%.JB]XY8:8P*IL0,@9^O1=#%-)IXPC,^[V?S!9@K(
MRDT*$3FQ!'_'G2/)W55D(TADIJ]X(;+U[/M!3EN#OI'-X_T,:3?D@6)8YL_X
M>\87_QO.\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0    ( ,X\Z%@'04UB
M@0   +$    0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L!
M A0#%     @ SCSH6/Q';[[O    *P(  !$              ( !KP   &1O
M8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ SCSH6)E<G",0!@  G"<  !,
M             ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M" #./.A8ZY2PT5H$  "1$   &               @($."   >&PO=V]R:W-H
M965T<R]S:&5E=#$N>&UL4$L! A0#%     @ SCSH6)^@&_"Q @  X@P   T
M             ( !G@P  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " #./.A8
MEXJ[',     3 @  "P              @ %Z#P  7W)E;',O+G)E;'-02P$"
M% ,4    " #./.A8&445]3<!   G @  #P              @ %C$   >&PO
M=V]R:V)O;VLN>&UL4$L! A0#%     @ SCSH6"0>FZ*M    ^ $  !H
M         ( !QQ$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#
M%     @ SCSH6&60>9(9 0  SP,  !,              ( !K!(  %M#;VYT
D96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  ]A,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="lgnd-20240708.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="lgnd-20240708.htm">lgnd-20240708.htm</File>
    <File>lgnd-20240708.xsd</File>
    <File>lgnd-20240708_lab.xml</File>
    <File>lgnd-20240708_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "lgnd-20240708.htm": {
   "nsprefix": "lgnd",
   "nsuri": "http://www.ligand.com/20240708",
   "dts": {
    "inline": {
     "local": [
      "lgnd-20240708.htm"
     ]
    },
    "schema": {
     "local": [
      "lgnd-20240708.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "lgnd-20240708_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lgnd-20240708_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 22
   },
   "report": {
    "R1": {
     "role": "http://www.ligand.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20240708.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20240708.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover page.",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0000886163-24-000053-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000886163-24-000053-xbrl.zip
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M4IF!BAL)/3%128:9*WB^DHJ)II9(H;FAJDN; L91P5YS+T5;2##,*IP[8^[
ME&6&.^\8\7:JX@[-O')K"2^NER/,4JOO5KZYEE^I,LFU=#$=N7A#Q,Q(3JH
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MO[^[W8-=C7+7]_Y_:?4]_Z^T_A]02P,$%     @ SCSH6$->T]U=&@  8HD
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M?L^"\:+MOI\LHQ/L-GPY^0502P,$%     @ SCSH6%(-LG:&"@  _U@  !4
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MQ@V,?[YYL7HF7_R]W#<O_@=02P,$%     @ SCSH6!<+8P'B!@  _3(  !4
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M-S X+GAS9%!+ 0(4 Q0    ( ,X\Z%A2#;)VA@H  /]8   5
M  "  : T  !L9VYD+3(P,C0P-S X7VQA8BYX;6Q02P$"% ,4    " #./.A8
M%PMC >(&  #],@  %0              @ %9/P  ;&=N9"TR,#(T,#<P.%]P
<<F4N>&UL4$L%!@     %  4 4 $  &Y&      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>lgnd-20240708_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="lgnd-20240708.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <startDate>2024-07-08</startDate>
            <endDate>2024-07-08</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-21">0000886163</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-22">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2024-07-08</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">LIGAND PHARMACEUTICALS INC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-33093</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">77-0160744</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">555 Heritage Drive, Suite 200</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">Jupiter</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">33458</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">550-7500</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">LGND</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
